While SLC35B2 knockout sensitized YAP1-activated melanoma cells toward Vemurafenib treatment, it did not completely stop melanoma cell proliferation, comparable to the strong, but limited effect of Vemurafenib single treatment on BRAFV600 mutant melanoma cells without YAP1 activation. Here, SLC35B2 is linked to melanoma.